Background Background An increased focus in
An increased focus in research specific to first-episode research specific to first-episode schizophrenia has provided a rapidly schizophrenia has provided a rapidly growing body of evidence that can be growing body of evidence that can be directly translated to clinical practice. directly translated to clinical practice.
Aims Aims To provide clinical
To provide clinical recommendations specific to effective recommendations specific to effective pharmacotherapy of first-episode pharmacotherapy of first-episode schizophrenia. schizophrenia.
Method Method Evidence from clinical trials
Evidence from clinical trials focused on the first-episode population is focused on the first-episode population is combined with data from other areas of combined with data from other areas of investigation. investigation.
Results

Results In first-episode psychosis,
In first-episode psychosis, when to initiate treatment is not always when to initiate treatment is not always clear, being intimately linked to challenges clear, being intimately linked to challenges regarding early detection and diagnosis. regarding early detection and diagnosis. There may be differences in antipsychotic There may be differences in antipsychotic dosing, patterns of response and dosing, patterns of response and sensitivity to side-effects. Adherence sensitivity to side-effects. Adherence appears to be even more problematic at appears to be even more problematic at this stage. this stage.
Conclusions Conclusions Clinicians currently
Clinicians currently treating early psychosis have considerably treating early psychosis have considerably more information to guide their decisionmore information to guide their decisionmaking.However, the speed at which the making.However, the speed at which the field is growing is a reminder to treatthis field is growing is a reminder to treatthis knowledge as a work in progress. knowledge as a work in progress.
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It is unlikely that there would have been a It is unlikely that there would have been a call for a paper of this sort even a decade call for a paper of this sort even a decade ago. Over the course of many years antiago. Over the course of many years antipsychotic treatment had come to be viewed psychotic treatment had come to be viewed as phase-specific, with distinctions really as phase-specific, with distinctions really confined to issues of acute confined to issues of acute v v. maintenance . maintenance treatment. The notion that treatment of treatment. The notion that treatment of psychosis was stage-dependent, that it varpsychosis was stage-dependent, that it varied as a function of where an individual ied as a function of where an individual was in the course of the illness, was not was in the course of the illness, was not viewed as particularly relevant. viewed as particularly relevant.
Within the last decade, however, stage Within the last decade, however, stage of illness has received considerably more of illness has received considerably more attention, a shift based on evidence arising attention, a shift based on evidence arising from opposite ends of the treatment contifrom opposite ends of the treatment continuum. By the early 1990s clozapine had nuum. By the early 1990s clozapine had been reintroduced for clinical use in a been reintroduced for clinical use in a number of countries, with accumulating number of countries, with accumulating evidence that it was superior even to other evidence that it was superior even to other second-generation antipsychotics in refracsecond-generation antipsychotics in refractory psychosis (Remington & Kapur, tory psychosis . Meanwhile, there was a growing 2000). Meanwhile, there was a growing body of evidence that individuals in the body of evidence that individuals in the early stages of psychosis might also be early stages of psychosis might also be distinguishable in terms of treatment, distinguishable in terms of treatment, both in terms of response and side-effects both in terms of response and side-effects (Lieberman (Lieberman et al et al, 1993 (Lieberman et al et al, , 1996 (Lieberman et al et al, ). , 1993 (Lieberman et al et al, , 1996 . Taken together, the evidence suggested Taken together, the evidence suggested that the pharmacotherapy of psychotic illthat the pharmacotherapy of psychotic illnesses, such as schizophrenia, needed to nesses, such as schizophrenia, needed to consider stage of illness. Decision-making consider stage of illness. Decision-making regarding individuals in the initial stages regarding individuals in the initial stages of psychosis is not the same as for those of psychosis is not the same as for those who have experienced multiple episodes, who have experienced multiple episodes, i.e. those in the 'chronic' phase of the i.e. those in the 'chronic' phase of the illness who frequently appear 'partially illness who frequently appear 'partially responsive'. There is, in addition, this responsive'. There is, in addition, this sub-population of individuals who, even sub-population of individuals who, even in the face of ongoing treatment with varin the face of ongoing treatment with various antipsychotics, show a suboptimal ious antipsychotics, show a suboptimal response, a group that is defined by the response, a group that is defined by the 'refractory' form of their illness. 'refractory' form of their illness.
Before proceeding further, it is worth Before proceeding further, it is worth noting that the term 'psychosis' is being noting that the term 'psychosis' is being used generically here. This is, at least in used generically here. This is, at least in part, related to the focus of the article, i.e. part, related to the focus of the article, i.e. early psychosis. At this particular point in early psychosis. At this particular point in treatment it is often impossible to make a treatment it is often impossible to make a clear diagnosis; however, based on existing clear diagnosis; however, based on existing knowledge in using antipsychotics, initially knowledge in using antipsychotics, initially the same principles apply. In contrast, over the same principles apply. In contrast, over the longer-term course of illness use of antithe longer-term course of illness use of antipsychotics may vary as a function of psychotics may vary as a function of diagnosis. diagnosis.
It also needs to be noted at the outset It also needs to be noted at the outset that the terms 'typical' and 'atypical' are that the terms 'typical' and 'atypical' are used here as a means of distinguishing used here as a means of distinguishing between the older and newer antipsychobetween the older and newer antipsychotics. Readers will be most familiar with tics. Readers will be most familiar with such a distinction, but there is reason to such a distinction, but there is reason to challenge this choice of terms and even challenge this choice of terms and even the underlying concept. With clinical the underlying concept. With clinical experience, it is apparent that such a experience, it is apparent that such a clear-cut dichotomy does not exist, particlear-cut dichotomy does not exist, particularly as new antipsychotics enter the cularly as new antipsychotics enter the market and we expand our measures of market and we expand our measures of outcome (Remington, 2003) . There is, in outcome (Remington, 2003) . There is, in fact, already ample evidence that the newer fact, already ample evidence that the newer agents are not equal on the various agents are not equal on the various domains, making it impossible to distindomains, making it impossible to distinguish two distinct classes (Waddington & guish two distinct classes (Waddington & O'Callaghan, 1997) . O'Callaghan, 1997 (Remington et al et al, 1998 (Remington et al et al, , 1998 (Remington et al et al, , 2001a . ). Recommendations are premised on the Recommendations are premised on the notion that we are dealing with a chronic notion that we are dealing with a chronic psychotic illness, such as schizophrenia, psychotic illness, such as schizophrenia, where antipsychotic treatment represents where antipsychotic treatment represents the cornerstone of effective treatment the cornerstone of effective treatment programmes. programmes.
METHOD METHOD
When should antipsychotic therapy When should antipsychotic therapy be introduced? be introduced?
Evidence from several lines of investigation Evidence from several lines of investigation suggests that early, effective interventions suggests that early, effective interventions improve outcome. For example, diminishimprove outcome. For example, diminishing the duration of untreated psychosis ing the duration of untreated psychosis (DUP) has been associated with better out-(DUP) has been associated with better outcome (Loebel come (Loebel et al et al, 1992; Scully , 1992; Scully et al et al, 1997; , 1997; Wyatt Wyatt et al et al, 1997; McGorry , 1997; McGorry et al et al, 2001) . , 2001). Similarly, it has been shown that with each Similarly, it has been shown that with each episode of psychosis, at least in the early episode of psychosis, at least in the early stages, it takes longer to establish response stages, it takes longer to establish response and the degree of response diminishes and the degree of response diminishes (Lieberman (Lieberman et al et al, 1996) . These types of , 1996). These types of findings provide support for the hypothesis findings provide support for the hypothesis that psychosis may represent some sort of that psychosis may represent some sort of 'toxic' process that incurs progressive 'toxic' process that incurs progressive damage in its untreated state (Wyatt, damage in its untreated state (Wyatt, 1995) . 1995).
Conceptually, this line of thinking fits Conceptually, this line of thinking fits with the notion that schizophrenia reprewith the notion that schizophrenia represents a neurodevelopmental, and possibly sents a neurodevelopmental, and possibly neuroprogressive, disorder (Censits neuroprogressive, disorder (Censits et al et al, , 1997; Lieberman, 1999; Finlay, 2001; 1997; Lieberman, 1999; Finlay, 2001; Weinberger, 2002) . Effective interventions Weinberger, 2002) . Effective interventions as early as possible should, at least in as early as possible should, at least in theory, carry the potential of delaying, theory, carry the potential of delaying, arresting, or even possibly reversing various arresting, or even possibly reversing various deficits that can be seen as early as the first deficits that can be seen as early as the first identified episode. identified episode.
The idea that early intervention The idea that early intervention improves outcome has spawned 'firstimproves outcome has spawned 'firstepisode episode' programmes worldwide and ' programmes worldwide and amongst their goals has been the identificaamongst their goals has been the identification of cases as soon as possible. That this is tion of cases as soon as possible. That this is a worthy and achievable objective gains a worthy and achievable objective gains support from evidence that in actual pracsupport from evidence that in actual practice DUP can be as much as a year or tice DUP can be as much as a year or longer, and we now have data to suggest longer, and we now have data to suggest that these types of programmes can that these types of programmes can effectively reduce this interval (Haas & effectively reduce this interval (Haas & Sweeney, 1992; Hafner & an der Heiden, Sweeney, 1992; Hafner & an der Heiden, 1997) . For example, the combined Norwe-1997). For example, the combined Norwegian/USA programme reported a dramatic gian/USA programme reported a dramatic reduction in DUP, from 118 to 20 weeks, reduction in DUP, from 118 to 20 weeks, with a focused programme that included a with a focused programme that included a public education component (Pelosi & public education component (Pelosi & Birchwood, 2003) . Birchwood, 2003) .
Clearly there is the opportunity for Clearly there is the opportunity for earlier intervention based on the length of earlier intervention based on the length of time psychotic symptoms go untreated. time psychotic symptoms go untreated. But is it possible to intervene even earlier? But is it possible to intervene even earlier? There is now a growing interest in the There is now a growing interest in the prodrome of schizophrenia, a stage lasting prodrome of schizophrenia, a stage lasting on average 5 years before the onset of frank on average 5 years before the onset of frank psychotic symptoms (Hafner & an der psychotic symptoms (Hafner & an der Heiden, 1997). Its presentation highlights Heiden, 1997) . Its presentation highlights other symptom domains, for example, other symptom domains, for example, affective (depression), cognitive (decreased affective (depression), cognitive (decreased attention, concentration), deficit (amotivaattention, concentration), deficit (amotivation, social withdrawal), but like later tion, social withdrawal), but like later stages of the illness is characterised by a stages of the illness is characterised by a functional decline. It is appealing to functional decline. It is appealing to imagine that an effective intervention stratimagine that an effective intervention strategy, here too, might favourably alter outegy, here too, might favourably alter outcome. Pharmacological intervention with come. Pharmacological intervention with antipsychotics immediately comes to mind, antipsychotics immediately comes to mind, given that use of these medications is given that use of these medications is integral to the longer-term management of integral to the longer-term management of schizophrenia. Moreover, there has been schizophrenia. Moreover, there has been evidence with the newer antipsychotics that evidence with the newer antipsychotics that their benefits may be seen along these other their benefits may be seen along these other symptom dimensions, in addition to psysymptom dimensions, in addition to psychotic symptoms chotic symptoms per se per se (Waddington & (Waddington & O'Callaghan, 1997; Buckley, 1999) . O'Callaghan, 1997; Buckley, 1999) .
The benefit of antipsychotic treatment The benefit of antipsychotic treatment initiated during the prodromal phase initiated during the prodromal phase remains unclear, if for no other reason than remains unclear, if for no other reason than lack of data. Several uncontrolled reports lack of data. Several uncontrolled reports have supported the symptomatic benefits have supported the symptomatic benefits of antipsychotic therapy (Cannon of antipsychotic therapy (Cannon et al et al, , 2002; Cornblatt 2002; Cornblatt et al et al, 2002 Cornblatt et al et al, ), although in , 2002 , although in one of these it was noted that benefits were one of these it was noted that benefits were seen with other psychotropics as well seen with other psychotropics as well (Cornblatt (Cornblatt et al et al, 2002) . One controlled trial , 2002). One controlled trial has reported the clinical benefits of lowhas reported the clinical benefits of lowdose risperidone and cognitive therapy dose risperidone and cognitive therapy when compared with supportive case when compared with supportive case management, with 4 of 32 individuals management, with 4 of 32 individuals (12.5%) in the former group becoming (12.5%) in the former group becoming psychotic during the 6-month treatment psychotic during the 6-month treatment period, in contrast to 10 out of 28 period, in contrast to 10 out of 28 (35.7%) in the latter (McGorry (35.7%) in the latter (McGorry et al et al, , 2000) . In an 8-week double-blind placebo-2000). In an 8-week double-blind placebocontrolled trial, olanzapine at mean doses controlled trial, olanzapine at mean doses of 8.0 of 8.0+ +3.1 mg 3.1 mg daily was found to be signifdaily was found to be significantly superior in the control of prodromal icantly superior in the control of prodromal symptoms (Woods symptoms (Woods et al et al, 2003 , 2003 Hoff , 2000 Hoff , , 2003 Hoff et al et al, , 2000) . There are interesting preliminary 2000). There are interesting preliminary data regarding the potential for antidata regarding the potential for antipsychotic treatment in the prodrome of psychotic treatment in the prodrome of schizophrenia, but reports await replication schizophrenia, but reports await replication and corroboration with controlled, masked and corroboration with controlled, masked studies. For a number of reasons, clinicians studies. For a number of reasons, clinicians are likely to be hesitant in instituting are likely to be hesitant in instituting antipsychotics at this point: a paucity of antipsychotics at this point: a paucity of empirical data; lack of biological markers empirical data; lack of biological markers in the face of non-specific, non-psychotic in the face of non-specific, non-psychotic symptoms; and recognition that even the symptoms; and recognition that even the newer antipsychotics carry with them the newer antipsychotics carry with them the potential for significant side-effects. potential for significant side-effects.
Finally, a comment is warranted Finally, a comment is warranted regarding outcome measures. Historically, regarding outcome measures. Historically, the focus was confined to positive the focus was confined to positive symptomatology, but this has changed consymptomatology, but this has changed considerably. It is common now to evaluate siderably. It is common now to evaluate pharmacological response on a number of pharmacological response on a number of clinical dimensions as well as side-effects clinical dimensions as well as side-effects (Remington, 2003) . Indeed, the list has (Remington, 2003) . Indeed, the list has expanded to the point where a simple expanded to the point where a simple dichotomous distinction between 'typical' dichotomous distinction between 'typical' and 'atypical' antipsychotics seems overly and 'atypical' antipsychotics seems overly simplistic (Waddington & O'Callaghan, simplistic (Waddington & O'Callaghan, 1997 1997; Tamminga, 1997; Stip, 2000) . Con-1997; Tamminga, 1997; Stip, 2000) . Concluding that the second-generation agents cluding that the second-generation agents represent first-line treatment for all individrepresent first-line treatment for all individuals with psychosis (including those with a uals with psychosis (including those with a first break) seems at this point a foregone first break) seems at this point a foregone conclusion. There are, however, at least conclusion. There are, however, at least three points of clarification that caution three points of clarification that caution against the uncontested acceptance of such against the uncontested acceptance of such an approach: an approach:
(a) (a) Most of the double-blind, controlled Most of the double-blind, controlled studies evaluating the newer studies evaluating the newer v v. older . older antipsychotics have been carried out in antipsychotics have been carried out in more chronic patients who have more chronic patients who have proven partially responsive. In fact, proven partially responsive. In fact, there are very few published investigathere are very few published investigations (see Table 1 ) that have focused tions (see Table 1 ) that have focused on the population with first-episode on the population with first-episode psychosis, and collectively the results psychosis, and collectively the results have not been particularly convincing have not been particularly convincing that the atypicals offer clinical superthat the atypicals offer clinical superiority (Lambert iority (Lambert et al et al, 1995; Emsley , 1995; Emsley et et al al, 1999; Sanger , 1999; Sanger et al et al, 1999; Lieberman , 1999; Lieberman et al et al, 2003) . A longer-term study (52 , 2003) . A longer-term study (52 weeks) comparing clozapine and chlorweeks) comparing clozapine and chlorpromazine found differences favouring promazine found differences favouring clozapine at 12 weeks, although the clozapine at 12 weeks, although the two groups were comparable by endtwo groups were comparable by endpoint (Lieberman point (Lieberman et al et al, 2003) . In the , 2003). In the one report indicating greater efficacy one report indicating greater efficacy for the atypical agent, i.e. olanzapine, for the atypical agent, i.e. olanzapine, the definition of first episode was the definition of first episode was extended to include individuals who extended to include individuals who could have been ill for as long as 5 could have been ill for as long as 5 years (Sanger years (Sanger et al et al, 1999) . , 1999).
(b) (b) It has been suggested that many of It has been suggested that many of the trials comparing typical and the trials comparing typical and atypical antipsychotics favoured the atypical antipsychotics favoured the latter, based on the use of inapprolatter, based on the use of inappropriately high doses of the comparative priately high doses of the comparative conventional antipsychotic (Geddes conventional antipsychotic (Geddes et al et al, 2000; Carpenter & Gold, , 2000; Carpenter & Gold, 2002) . Although this topic will be 2002). Although this topic will be addressed in more detail in the next addressed in more detail in the next section, suffice it to say that there is section, suffice it to say that there is compelling evidence to support this compelling evidence to support this claim. claim. From the standpoint of side-effects, much has been made of the superiority much has been made of the superiority of the newer antipsychotics with of the newer antipsychotics with respect to extrapyramidal side-effects respect to extrapyramidal side-effects (EPS), perhaps the most problematic (EPS), perhaps the most problematic adverse event associated with the adverse event associated with the conventional agents, especially the conventional agents, especially the high-potency group (e.g. haloperidol). high-potency group (e.g. haloperidol).
The advantage of the atypicals in this The advantage of the atypicals in this regard again appears to be related, at regard again appears to be related, at least in part, to inappropriate dosing least in part, to inappropriate dosing of the typical antipsychotics used as of the typical antipsychotics used as the comparator in many of these trials the comparator in many of these trials (Leucht (Leucht et al et al, 1999; Geddes , 1999; Geddes et al et al, , 2000) . Moreover, accumulating experi-2000) . Moreover, accumulating experience with the newer antipsychotics has ence with the newer antipsychotics has indicated that they are not without indicated that they are not without the risk of notable side-effects, in the risk of notable side-effects, in particular, weight gain, diabetes particular, weight gain, diabetes and cardiovascular risk (Casey, 1996; and cardiovascular risk (Casey, 1996; Cunningham Owens, 1996; Umbricht Cunningham Owens, 1996; Umbricht & Kane, 1996; Wirshing & Kane, 1996; Wirshing et al et al, 1998 Wirshing et al et al, , , 1998 Wirshing et al et al, , 1999 Wirshing et al et al, , 2002 Allison 1999 Allison , 2002 Allison et al et al 1999; 1999; Allison & Casey, 2001 ). Indeed, it has Allison & Casey, 2001). Indeed, it has been suggested that these adverse been suggested that these adverse events have come to represent the events have come to represent the 'EPS' 'EPS' of this new generation of of this new generation of antipsychotics. antipsychotics.
On the other side of the coin, there On the other side of the coin, there are several issues that need to be considered are several issues that need to be considered before dismissing the idea that the atypicals before dismissing the idea that the atypicals should be first-line treatment. It has should be first-line treatment. It has been demonstrated that individuals with a been demonstrated that individuals with a first-episode psychosis respond well to first-episode psychosis respond well to antipsychotic treatment, with as many as antipsychotic treatment, with as many as 80% recovering symptomatically from 80% recovering symptomatically from their initial episode (Tohen their initial episode (Tohen et al et al, 1992; , 1992; Lieberman Lieberman et al et al, 1993) . With such a high , 1993). With such a high response rate, a 'ceiling effect' cannot be response rate, a 'ceiling effect' cannot be ruled out; that is, it becomes difficult to ruled out; that is, it becomes difficult to tease apart potential differences between tease apart potential differences between different treatment interventions. In addidifferent treatment interventions. In addition, we have expanded our definition of tion, we have expanded our definition of outcome considerably in recent years, no outcome considerably in recent years, no longer focusing only on the control of posilonger focusing only on the control of positive symptoms. Numerous other dimentive symptoms. Numerous other dimensions (e.g. cognition, affect, quality of life) sions (e.g. cognition, affect, quality of life) are now the subject of evaluation and there are now the subject of evaluation and there are a paucity of data that allow a compariare a paucity of data that allow a comparison of older and newer agents on these son of older and newer agents on these different dimensions (Geddes different dimensions (Geddes et al et al, 2000; Remington, 2003) . It may well be that future work 2003). It may well be that future work demonstrates detectable differences on one demonstrates detectable differences on one or more of these dimensions, and the potenor more of these dimensions, and the potential scope of these differences may extend tial scope of these differences may extend even beyond clinical symptoms. For exameven beyond clinical symptoms. For example, we now have data to suggest that there ple, we now have data to suggest that there are also detectable changes morphologiare also detectable changes morphologically (Chakos cally (Chakos et al et al, 1995; Andersson , 1995; Andersson et al et al, , 2002) . What these changes mean is not 2002). What these changes mean is not yet fully understood, but it speaks not only yet fully understood, but it speaks not only to choice of antipsychotic but also to this to choice of antipsychotic but also to this issue of early intervention and improved issue of early intervention and improved outcome. outcome.
At this point there is still insufficient At this point there is still insufficient evidence from the standpoint of efficacy evidence from the standpoint of efficacy to support the position that the newer antito support the position that the newer antipsychotics represent first-line treatment. psychotics represent first-line treatment. The most compelling argument presently The most compelling argument presently rests upon side-effects. First, it has been rests upon side-effects. First , 1998) , and once again the argument could 1998), and once again the argument could be made that the use of comparatively highbe made that the use of comparatively higher doses of these drugs could account for er doses of these drugs could account for these reported differences in tardive dyskithese reported differences in tardive dyskinesia rates. However, this does not appear nesia rates. However, this does not appear to be the case. A recent study reported a to be the case. A recent study reported a 12-month incidence of probable and persis-12-month incidence of probable and persistent tardive dyskinesia to be 12.3% in a tent tardive dyskinesia to be 12.3% in a group of individuals with first-episode psygroup of individuals with first-episode psychosis treated with haloperidol at a mean chosis treated with haloperidol at a mean dose of 2.8 mg/day (Oosthuizen dose of 2.8 mg/day (Oosthuizen et al et al, , 2003) . Indirect evidence also can be found 2003). Indirect evidence also can be found from looking at high-risk populations, i.e. from looking at high-risk populations, i.e. the geriatric population, individuals with the geriatric population, individuals with borderline tardive dyskinesia, where eviborderline tardive dyskinesia, where evidence once again supports the benefit of dence once again supports the benefit of atypicals in terms of tardive dyskinesia risk, atypicals in terms of tardive dyskinesia risk, even when comparable doses of the even when comparable doses of the conventional drugs are employed (Jeste conventional drugs are employed (Jeste et et al al, 1999 (Jeste et et al al, , 1999a (Jeste et et al al, a, ,b b, 2000 Dolder & Jeste, 2003) . Dolder & Jeste, 2003) . There are, in addition, data to indicate There are, in addition, data to indicate that across other side-effects the atypical that across other side-effects the atypical antipsychotics may be better tolerated, as antipsychotics may be better tolerated, as measured by discontinuation rates (Emsley measured by discontinuation rates (Emsley et al et al, 1999) . Having said this, the new anti-, 1999). Having said this, the new antipsychotics have attuned us to a different psychotics have attuned us to a different profile of adverse events that cannot be profile of adverse events that cannot be ignored. For example, weight gain has ignored. For example, weight gain has become a significant issue, particularly with become a significant issue, particularly with several of the newer compounds (Allison several of the newer compounds (Allison et al et al, 1999; Wirshing , 1999; Wirshing et al et al, 1999; Allison , 1999; Allison & Casey, 2001; Nasrallah, 2003), and & Casey, 2001; Nasrallah, 2003) , and patients with first-episode psychosis patients with first-episode psychosis exposed to these compounds appear to be exposed to these compounds appear to be s 7 9 s 7 9 , 2003) . These risks are only compounded when one considers that treatcompounded when one considers that treatment is being initiated in late adolescence ment is being initiated in late adolescence and may be lifelong. Moreover, this is a and may be lifelong. Moreover, this is a population that has a higher propensity of population that has a higher propensity of numerous other cardiovascular risk factors numerous other cardiovascular risk factors (Allebeck & Wistedt, 1986; Mortensen & (Allebeck & Wistedt, 1986; Mortensen & Juel, 1993; Brown Juel, 1993; Brown et al et al, 2000; Osby , 2000; Osby et al et al, , 2000) , and for various reasons has dimin-2000), and for various reasons has diminished access to medical care (Felker ished access to medical care (Felker et al et al, , 1996) . More recent concerns with ziprasi-1996). More recent concerns with ziprasidone and sertindole regarding potential done and sertindole regarding potential cardiac changes, specifically QTc prolongacardiac changes, specifically QTc prolongation, have reminded clinicians of potential tion, have reminded clinicians of potential cardiac risks (Glassman & Bigger, 2001; cardiac risks (Glassman & Bigger, 2001; Taylor, 2003) , and although the risk is Taylor, 2003) , and although the risk is low it can be potentially life-threatening. low it can be potentially life-threatening. It is impossible to disregard issues of this It is impossible to disregard issues of this sort in decision-making regarding antisort in decision-making regarding antipsychotic choice; indeed, there is reason psychotic choice; indeed, there is reason to argue that these types of side effects to argue that these types of side effects are of no less concern than tardive are of no less concern than tardive dyskinesia. dyskinesia.
To summarise, there is at present a lack To summarise, there is at present a lack of compelling evidence that the newer antiof compelling evidence that the newer antipsychotics are clinically superior in the psychotics are clinically superior in the population with first-episode psychosis, population with first-episode psychosis, and for now the argument regarding choice and for now the argument regarding choice really rests upon side-effects. The increased really rests upon side-effects. The increased risk of tardive dyskinesia with conventional risk of tardive dyskinesia with conventional antipsychotics favours using the atypicals; antipsychotics favours using the atypicals; conversely, the risk of adverse events, such conversely, the risk of adverse events, such as weight gain, diabetes, and other cardioas weight gain, diabetes, and other cardiovascular events associated with the newer vascular events associated with the newer antipsychotics, counters their straightantipsychotics, counters their straightforward acceptance as first-line treatment. forward acceptance as first-line treatment. There is, however, a difference with respect There is, however, a difference with respect to tardive dyskinesia, with the newer agents to tardive dyskinesia, with the newer agents at a lower risk in this regard (whereas there at a lower risk in this regard (whereas there are differences in acute EPS between the are differences in acute EPS between the atypicals (Leucht atypicals (Leucht et al et al, 1999) , as of yet , 1999), as of yet there is no concrete evidence that they there is no concrete evidence that they differ in terms of diminished tardive differ in terms of diminished tardive dyskinesia risk). There do appear to be dyskinesia risk). There do appear to be distinguishable differences between these distinguishable differences between these medications regarding such side-effects as medications regarding such side-effects as weight gain and QTc prolongation. Thus, weight gain and QTc prolongation. Thus, the clinician may move to the newer the clinician may move to the newer antipsychotics as first-line treatment to antipsychotics as first-line treatment to avoid tardive dyskinesia, and then choose avoid tardive dyskinesia, and then choose between these based on their relative risk between these based on their relative risk for other relevant side-effects. for other relevant side-effects.
What is an appropriate dose? What is an appropriate dose?
To address this question properly it is To address this question properly it is necessary to briefly review what has taken necessary to briefly review what has taken place with antipsychotic dosing over the place with antipsychotic dosing over the years. First, schizophrenia is an illness years. First, schizophrenia is an illness where a significant portion of individuals where a significant portion of individuals demonstrate a suboptimal response -with demonstrate a suboptimal response -with the conventional antipsychotics, for examthe conventional antipsychotics, for example, data indicate that as many as 25% fail ple, data indicate that as many as 25% fail to respond (Brenner to respond (Brenner et al et al, 1990) . It is not so , 1990). It is not so surprising that in an effort to achieve surprising that in an effort to achieve response clinicians moved to the use of response clinicians moved to the use of higher doses; however, the cardiovascular higher doses; however, the cardiovascular side-effects, i.e. orthostatic hypotension, of side-effects, i.e. orthostatic hypotension, of the lower-potency antipsychotics to some the lower-potency antipsychotics to some extent acted as a rate-limiting step in this extent acted as a rate-limiting step in this regard. With the high-potency antipsychoregard. With the high-potency antipsychotics like haloperidol, this was not such a tics like haloperidol, this was not such a problem and there was a progressive problem and there was a progressive increase in dosing. By the 1980s high-dose increase in dosing. By the 1980s high-dose approaches were even advocated (e.g. rapid approaches were even advocated (e.g. rapid neuroleptisation), and antipsychotic doses neuroleptisation), and antipsychotic doses increased to over three times those increased to over three times those employed with the low-potency agents employed with the low-potency agents (Baldessarini (Baldessarini et al et al, 1984) . In practice it , 1984). In practice it was not uncommon to see daily doses well was not uncommon to see daily doses well in excess of haloperidol 20 mg equivalents. in excess of haloperidol 20 mg equivalents.
By the late 1980s, this practice was By the late 1980s, this practice was being called into question. A review of the being called into question. A review of the controlled studies indicated that there controlled studies indicated that there was no evidence to support the clinical was no evidence to support the clinical superiority of high-dose therapy, leading superiority of high-dose therapy, leading to the recommendation that doses in the to the recommendation that doses in the range of 3-12 mg haloperidol equivalents range of 3-12 mg haloperidol equivalents reflected a more appropriate therapeutic reflected a more appropriate therapeutic range (Baldessarini range (Baldessarini et al et al, 1988) . Subsequent , 1988) . Subsequent analyses supported this finding (Bollini analyses supported this finding (Bollini et al et al, , 1994) . 1994).
More recently there has been even More recently there has been even further support for these lower doses based further support for these lower doses based on on in vivo in vivo evidence arising from neuroevidence arising from neuroimaging, in particular positron emission imaging, in particular positron emission tomography (PET). For example, it has tomography (PET There are now clinical data that offer There are now clinical data that offer credence to this notion, data involving credence to this notion, data involving patients with first-episode psychosis. This patients with first-episode psychosis. This is an important methodological issue as is an important methodological issue as these individuals appear to differ from the these individuals appear to differ from the more chronic population in terms of treatmore chronic population in terms of treatment response as well as sensitivity to ment response as well as sensitivity to side-effects, such as EPS (McEvoy, 1986 ; side-effects, such as EPS (McEvoy, 1986; Lieberman Lieberman et al et al, 1993 , 1996 Aguilar , 1993 Aguilar , , 1996 Aguilar et et al al, 1994; Robinson , 1994; Robinson et al et al, 1999 Robinson et al et al, , 1999b . Zhang-). ZhangWong and colleagues, for example, found Wong and colleagues, for example, found that 82% of their patients with first-episode that 82% of their patients with first-episode psychosis were treated effectively with psychosis were treated effectively with haloperidol 2-5 mg daily. Their study haloperidol 2-5 mg daily. Their study allowed those who had not responded to allowed those who had not responded to then be treated with higher doses (10-then be treated with higher doses (10-20 mg/day), but this subgroup continued 20 mg/day), but this subgroup continued to be less responsive. EPS were reported in to be less responsive. EPS were reported in 13% of the 2 mg group, in contrast to 13% of the 2 mg group, in contrast to 55% for those who receive 5 mg (Zhang-55% for those who receive 5 mg (ZhangWong Wong et al et al, 1999) . In a double-blind fixed, , 1999). In a double-blind fixed, flexible design comparing risperidone with flexible design comparing risperidone with haloperidol over 6 weeks, Emsley haloperidol over 6 weeks, Emsley et al et al (1999) reported mean end-point doses of (1999) reported mean end-point doses of 6.1 mg and 5.6 mg, respectively, despite 6.1 mg and 5.6 mg, respectively, despite the fact that doses could be increased to the fact that doses could be increased to 16 mg daily for each. 16 mg daily for each.
A more recent double-blind study A more recent double-blind study completed at this centre evaluated the completed at this centre evaluated the relationship between D relationship between D 2 2 occupancy and occupancy and clinical response, as well as side-effects, in clinical response, as well as side-effects, in 23 patients with first-episode psychosis 23 patients with first-episode psychosis (Kapur (Kapur et al et al, 1999) . Patients were randomly , 1999). Patients were randomly assigned to haloperidol 1 mg or 2.5 mg assigned to haloperidol 1 mg or 2.5 mg daily. If they failed to demonstrate 'much' daily. If they failed to demonstrate 'much' or 'very much' improvement over 2 weeks, or 'very much' improvement over 2 weeks, the dose was increased to 5 mg for another the dose was increased to 5 mg for another 2 weeks. Results indicated that D 2 weeks. Results indicated that D 2 2 occuoccupancy could be used to predict clinical pancy could be used to predict clinical response, in that a threshold set at 65% response, in that a threshold set at 65% was predictive of response with 80% sensiwas predictive of response with 80% sensitivity. Of the 10 identified responders after tivity. Of the 10 identified responders after 2 weeks, 2 were receiving haloperidol 1 mg 2 weeks, 2 were receiving haloperidol 1 mg whereas 8 received 2.5 mg. Only 2 of these whereas 8 received 2.5 mg. Only 2 of these 10 individuals had D 10 individuals had D 2 2 occupancy below occupancy below 65%. Completed data were available for 65%. Completed data were available for 11 of the identified non-responders who 11 of the identified non-responders who went on to receive haloperidol 5 mg/day. went on to receive haloperidol 5 mg/day. Seven of this group had D Seven of this group had D 2 2 occupancies occupancies below 65% prior to this increase, and of below 65% prior to this increase, and of these 6 (85.7%) improved with the higher these 6 (85.7%) improved with the higher dose. In contrast, 1 out of 4 (25%) who dose. In contrast, 1 out of 4 (25%) who already had occupancies beyond 65% already had occupancies beyond 65% before the dose increment showed before the dose increment showed s 8 0 s 8 0 improvement. In terms of EPS, 3 out of the improvement. In terms of EPS, 3 out of the 23 (13%) treated with either haloperidol 23 (13%) treated with either haloperidol 1 mg or 2.5 mg developed EPS, whereas 7 1 mg or 2.5 mg developed EPS, whereas 7 out of 12 (58%) experienced EPS with the out of 12 (58%) (Schroder et al et al, 1998; Silvestri , 1998; Silvestri et al et al, 2000) . At the , 2000). At the same time however, the ageing process is same time however, the ageing process is associated with progressive loss of D associated with progressive loss of D 2 2 receptors, at least as observed in control receptors, at least as observed in control populations (Seeman populations (Seeman et al et al, 1987), and this , 1987) , and this may account for the progressively lower may account for the progressively lower doses that are required in older individuals. doses that are required in older individuals.
It is interesting to note that the data do It is interesting to note that the data do not support the position of clinical supernot support the position of clinical superiority with doses in excess of haloperidol iority with doses in excess of haloperidol 12 mg equivalents daily. This finding 12 mg equivalents daily. This finding dovetails with a more recent meta-analysis dovetails with a more recent meta-analysis comparing the benefits of the newer anticomparing the benefits of the newer antipsychotics psychotics v v. conventional antipsychotics. . conventional antipsychotics. When haloperidol doses When haloperidol doses 4 412 mg daily 12 mg daily were evaluated, the atypicals had no benewere evaluated, the atypicals had no benefits in terms of efficacy or tolerability fits in terms of efficacy or tolerability (although they did show fewer EPS) (although they did show fewer EPS) (Geddes (Geddes et al et al, 2000) . , 2000). Having information regarding equiHaving information regarding equipotent dosing guidelines for the different potent dosing guidelines for the different antipsychotics is important for clinicians, antipsychotics is important for clinicians, who must often switch antipsychotics who must often switch antipsychotics because of issues related to efficacy and/or because of issues related to efficacy and/or side-effects. Past guidelines have depended side-effects. Past guidelines have depended on pharmacokinetic and clinical data, but on pharmacokinetic and clinical data, but the more recent PET evidence allows for the more recent PET evidence allows for greater precision in these calculations. This greater precision in these calculations. This line of thinking is based on the premise that line of thinking is based on the premise that D D 2 2 occupancy is shared in common by all occupancy is shared in common by all antipsychotics, typical as well as atypical, antipsychotics, typical as well as atypical, and that the and that the in vitro in vitro affinity of a drug for affinity of a drug for the D the D 2 2 receptor remains the single best receptor remains the single best predictor of its dose in the clinical setting predictor of its dose in the clinical setting (Creese (Creese et al et al, 1976; Seeman , 1976; Seeman et al et al, 1976 (Seeman & Tallerico, 1999; Kapur & (Seeman & Tallerico, 1999; Kapur & Seeman, 2000) , making the precise calcula- Seeman, 2000) , making the precise calculation of their equipotent values more diffition of their equipotent values more difficult. Acknowledging this caveat, however, cult. Acknowledging this caveat, however, Table 2 outlines comparative doses  Table 2 outlines comparative doses between several conventional antipsychobetween several conventional antipsychotics, including haloperidol, evaluated at tics, including haloperidol, evaluated at our centre with PET and several of the our centre with PET and several of the newer agents (olanzapine, risperidone, newer agents (olanzapine, risperidone, ziprasidone). ziprasidone).
How long should antipsychotic How long should antipsychotic therapy be employed? therapy be employed?
This question really entails two compoThis question really entails two components: (a) how long should a trial last to nents: (a) how long should a trial last to establish response; and (b) how long should establish response; and (b) how long should someone who has been successfully treated someone who has been successfully treated continue with antipsychotic therapy? continue with antipsychotic therapy?
For many years it has been customary For many years it has been customary to carry out a trial of 6-8 weeks to to carry out a trial of 6-8 weeks to establish response. Work specifically involestablish response. Work specifically involving patients with first-episode psychosis ving patients with first-episode psychosis reported mean and median times to remisreported mean and median times to remission of 35.7 and 11 weeks, respectively sion of 35.7 and 11 weeks, respectively (Lieberman (Lieberman et al et al, 1993) . It is important to , 1993). It is important to keep in mind that this same line of investikeep in mind that this same line of investigation found time to response increased gation found time to response increased with subsequent episodes (Lieberman with subsequent episodes (Lieberman et et al al, 1996) , a finding that is in keeping with , 1996), a finding that is in keeping with reports involving more refractory patients reports involving more refractory patients indicating that a longer trial may be indicating that a longer trial may be required, perhaps in the range of 3 months required, perhaps in the range of 3 months or more (Meltzer, 1989; Smith or more (Meltzer, 1989; Smith et al et al, 1996; , 1996; Wilson, 1996) . Wilson, 1996) .
A troubling question for many clini-A troubling question for many clinicians is how long to continue antipsychotic cians is how long to continue antipsychotic therapy in those with a first-episode psytherapy in those with a first-episode psychosis who have responded effectively to chosis who have responded effectively to antipsychotic therapy. It is known that as antipsychotic therapy. It is known that as many as 80% of patients with first-episode many as 80% of patients with first-episode psychosis will show symptom resolution psychosis will show symptom resolution with treatment (Tohen with treatment (Tohen et al et al, 1992; Lieber-, 1992; Lieberman man et al et al, 1993) , making this a common , 1993), making this a common dilemma with this population. The notion dilemma with this population. The notion of taking antipsychotic medication for a of taking antipsychotic medication for a lifetime following a single psychotic epilifetime following a single psychotic episode is not an appealing option. Studies sode is not an appealing option. Studies have indicated that there is a relapse have indicated that there is a relapse rate of 40-60% during the first year in rate of 40-60% during the first year in individuals who go untreated following individuals who go untreated following recovery from a first-episode psychosis recovery from a first-episode psychosis (Kane (Kane et al et al, 1982; Crow , 1982; Crow et al et al, 1986 Crow et al et al, ), lead-, 1986 , leading to the recommendation that pharmaing to the recommendation that pharmacological treatment continues for at least cological treatment continues for at least 1-2 years (Kissling, 1991; Frances, 1998) . 1-2 years (Kissling, 1991; Frances, 1998) . There is an appeal to these guidelines, as There is an appeal to these guidelines, as they offer a compromise for both patients they offer a compromise for both patients and clinicians. For patients it means that and clinicians. For patients it means that there is a potential 'end' in sight to medithere is a potential 'end' in sight to medication use; for clinicians, it also offers some cation use; for clinicians, it also offers some type of end-point to the prescribing of antitype of end-point to the prescribing of antipsychotics in individuals where the diagpsychotics in individuals where the diagnosis may be less than clear. However, nosis may be less than clear. However, more recent evidence injects a note of more recent evidence injects a note of caution to the goal of antipsychotic disconcaution to the goal of antipsychotic discontinuation (Robinson tinuation (Robinson et al et al, 1999 (Robinson et al et al, , 1999a . Speci-). Specifically, in a 5-year follow-up of 104 fically, in a 5-year follow-up of 104 individuals who had responded to treatindividuals who had responded to treatment of their index episode, discontinuing ment of their index episode, discontinuing antipsychotic therapy increased the risk antipsychotic therapy increased the risk of relapse by almost 5 times. Moreover, of of relapse by almost 5 times. Moreover, of 15 individuals who had their first relapse 15 individuals who had their first relapse after 2 years of stability, 8 had discontinued after 2 years of stability, 8 had discontinued medication. Even more sobering are data medication. Even more sobering are data indicating that in a group of individuals indicating that in a group of individuals with recent-onset schizophrenia who diswith recent-onset schizophrenia who discontinued antipsychotic medication 78% continued antipsychotic medication 78% experienced symptom exacerbation or experienced symptom exacerbation or relapse within 1 year, with the figure relapse within 1 year, with the figure climbing to 96% by 2 years (Gitlin climbing to 96% by 2 years (Gitlin et al et al, , 2001 (Gitlin et al et al, , ). 2001 .
This raises the possibility that an even This raises the possibility that an even more conservative approach may need to more conservative approach may need to be considered, i.e. continuous antipsychotic be considered, i.e. continuous antipsychotic treatment at the lowest possible dose, at treatment at the lowest possible dose, at least for those where there is convincing least for those where there is convincing evidence that the diagnosis is compatible evidence that the diagnosis is compatible with schizophrenia. Unfortunately, longerwith schizophrenia. Unfortunately, longerterm treatment adherence is a major term treatment adherence is a major hurdle with this population, perhaps even hurdle with this population, perhaps even more so than with those in later stages of more so than with those in later stages of the illness. This has been brought home in the illness. This has been brought home in a recent study that followed individuals a recent study that followed individuals with first-episode psychosis for a 1-year with first-episode psychosis for a 1-year period after discharge. Only 37% mainperiod after discharge. Only 37% maintained their medication over this interval; tained their medication over this interval; in contrast, 51% had gaps of 30 days or in contrast, 51% had gaps of 30 days or longer, with an average total time off longer, with an average total time off medication of approximately 7 months medication of approximately 7 months s 81 s 81 2001b b) may offer approaches that can ) may offer approaches that can address the practical limitations nonaddress the practical limitations nonadherence brings to bear on the successful adherence brings to bear on the successful management of these individuals. management of these individuals.
DISCUSSION DISCUSSION
Just as we now acknowledge that schizoJust as we now acknowledge that schizophrenia is heterogeneous in its nature, phrenia is heterogeneous in its nature, we must also recognise that its pharmawe must also recognise that its pharmacotherapy varies over the illness' course cotherapy varies over the illness' course in ways that are not confined to acute in ways that are not confined to acute v v. . maintenance treatment. The issues and maintenance treatment. The issues and decision-making that apply to first-episode decision-making that apply to first-episode psychosis may not be the same for those psychosis may not be the same for those who are in later stages of the illness, or those who are in later stages of the illness, or those who have remained refractory to standard who have remained refractory to standard interventions. Individuals in a first-episode interventions. Individuals in a first-episode psychosis are unique. Diagnosis is often less psychosis are unique. Diagnosis is often less clear than for those who have been followed clear than for those who have been followed over a longer interval; patients with firstover a longer interval; patients with firstepisode psychosis seem more sensitive to episode psychosis seem more sensitive to antipsychotic medications in terms of sideantipsychotic medications in terms of sideeffects but, at the same time, appear more effects but, at the same time, appear more responsive; dosing may be somewhat differresponsive; dosing may be somewhat different in these individuals ent in these individuals v v. those in later . those in later stages of the illness; and, the notion of antistages of the illness; and, the notion of antipsychotic discontinuation is more of an psychotic discontinuation is more of an issue in this group. Current evidence has issue in this group. Current evidence has been reviewed with respect to recommendabeen reviewed with respect to recommendations that can be used in the clinical setting. tions that can be used in the clinical setting. It almost goes without saying, however, that It almost goes without saying, however, that this is a work in progress -further advances this is a work in progress -further advances will undoubtedly shed more light on these will undoubtedly shed more light on these issues but raise yet more questions. For issues but raise yet more questions. For clinicians this is a double-edged sword. clinicians this is a double-edged sword. These advances add additional layers of These advances add additional layers of complexity to their decision-making and complexity to their decision-making and demand that they stay abreast of changes demand that they stay abreast of changes in a field that is expanding rapidly, while in a field that is expanding rapidly, while at the same time setting the stage for more at the same time setting the stage for more refined interventions and, ideally, better refined interventions and, ideally, better outcomes. outcomes. 
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